CINCINNATI--(BUSINESS WIRE)--Aug. 17, 2015--
Meridian Bioscience, Inc. announces that on August 11, 2015, the Board
of Directors of Meridian Bioscience, Inc. elected two new independent
directors, Catherine A. Sazdanoff and John C. McIlwraith, effective
August 14, 2015.
Ms. Sazdanoff is the CEO and President of Sazdanoff Consulting LLC,
specializing in business development, management and strategy
consulting. In addition, she is Strategic Advisor to mProve Health LLC,
a mobile health technology company located in Arlington, Virginia. From
2006 to 2015, Ms. Sazdanoff held a number of executive positions with
Takeda Pharmaceutical International, Inc. including Vice President, Head
of Corporate Projects, VP, Global Business Development and VP, Corporate
Development. Prior to her time at Takeda, Ms. Sazdanoff spent 22 years
with Abbott Laboratories, where she held numerous executive positions.
Ms. Sazdanoff received a B.A. from the University of Notre Dame and a
J.D. from Northwestern University School of Law.
Mr. McIlwraith co-founded Allos Ventures, a venture capital firm, in
March 2010 and has served as a Managing Director there since that time.
Prior to founding Allos Ventures, Mr. McIlwraith was a Managing Director
of Blue Chip Venture Company, a Cincinnati-based venture capital and
private equity firm, which he joined in 1997. He has served on the board
of directors of more than 20 healthcare or information technology
companies, and is currently the lead director of Assurex Health, Inc.,
an informatics-based precision medicine company providing treatment
decision support to health care providers for behavioral health
conditions. Prior to 1997, Mr. McIlwraith served as Senior Vice
President of Strategic Planning and General Counsel of publicly-traded
Quantum Health Resources, Inc., and was a partner in the Jones Day law
firm. Mr. McIlwraith received a B.A. from Hillsdale College and a J.D.
from Case Western Reserve University.
John A. Kraeutler, Chairman and Chief Executive Officer, commented,
“With the election of Catherine and John to the Board of Directors of
Meridian Bioscience we have added key strategic and operating strengths
to help guide our future growth. Our Nominating Committee has been
working diligently for more than a year to add specific skills to the
Board. During that period, we have met and interviewed many talented
individuals and we are very pleased that Catherine and John have agreed
to join our team. I look forward to working closely with both Catherine
and John, along with our existing directors, as we build a strong future
for Meridian Bioscience.”
Meridian is a fully integrated life science company that develops,
manufactures, markets and distributes a broad range of innovative
diagnostic test kits, purified reagents and related products and offers
biopharmaceutical enabling technologies. Utilizing a variety of methods,
these products and diagnostic tests provide accuracy, simplicity and
speed in the early diagnosis and treatment of common medical conditions,
such as gastrointestinal, viral and respiratory infections. Meridian’s
diagnostic products are used outside of the human body and require
little or no special equipment. The Company's products are designed to
enhance patient well-being while reducing the total outcome costs of
health care. Meridian has strong market positions in the areas of
gastrointestinal and upper respiratory infections, serology,
parasitology and fungal disease diagnosis. In addition, Meridian is a
supplier of rare reagents, specialty biologicals and related
technologies used by biopharmaceutical companies engaged in research for
new drugs and vaccines. The Company markets its products and
technologies to hospitals, reference laboratories, research centers,
diagnostics manufacturers and biotech companies in more than 60
countries around the world. The Company’s shares are traded on the
NASDAQ Global Select Market, symbol VIVO. Meridian's website address is www.meridianbioscience.com.
View source version on businesswire.com: http://www.businesswire.com/news/home/20150817005796/en/
Source: Meridian Bioscience, Inc.
Meridian Bioscience, Inc.
John A. Kraeutler, Chief Executive